Feillet F, Arnoux J, Delgado M, Burlina A, Chabrol B, Kucuksayrac E
J Inherit Metab Dis. 2024; 48(1):e12796.
PMID: 39237321
PMC: 11667744.
DOI: 10.1002/jimd.12796.
Pinto A, Ahring K, Almeida M, Ashmore C, Belanger-Quintana A, Burlina A
Nutrients. 2024; 16(13).
PMID: 38999811
PMC: 11243388.
DOI: 10.3390/nu16132064.
Gonzalez-Lamuno D, Morencos C, Arrieta F, Venegas E, Vicente-Rodriguez G, Casajus J
Nutrients. 2024; 16(5).
PMID: 38474766
PMC: 10933964.
DOI: 10.3390/nu16050639.
Ilgaz F, Ford S, ODriscoll M, MacDonald A
Nutrients. 2023; 15(20).
PMID: 37892429
PMC: 10610305.
DOI: 10.3390/nu15204352.
Delsoglio M, Capener R, MacDonald A, Daly A, Ashmore C, Donald S
Nutrients. 2023; 15(16).
PMID: 37630788
PMC: 10459832.
DOI: 10.3390/nu15163598.
Evaluation of a New Glycomacropeptide-Based Protein Substitute in Powdered and Liquid Format in Patients with PKU.
Delsoglio M, Capener R, MacDonald A, Daly A, Ashmore C, Ellerton C
Nutrients. 2023; 15(16).
PMID: 37630769
PMC: 10459497.
DOI: 10.3390/nu15163580.
Preliminary Data on Free Use of Fruits and Vegetables Containing Phenylalanine 76-100 mg/100 g of Food in 16 Children with Phenylketonuria: 6 Months Follow-Up.
Pinto A, Daly A, Rocha J, Ashmore C, Evans S, Jackson R
Nutrients. 2023; 15(13).
PMID: 37447372
PMC: 10347155.
DOI: 10.3390/nu15133046.
Therapeutics in paediatric genetic diseases: Current and future landscape.
Koh A, Jamuar S
Singapore Med J. 2023; 64(1):7-16.
PMID: 36722512
PMC: 9979794.
DOI: 10.4103/singaporemedj.SMJ-2021-376.
Complications of the Low Phenylalanine Diet for Patients with Phenylketonuria and the Benefits of Increased Natural Protein.
McWhorter N, Ndugga-Kabuye M, Puurunen M, Ernst S
Nutrients. 2022; 14(23).
PMID: 36500989
PMC: 9740314.
DOI: 10.3390/nu14234960.
Body Composition in Adolescent PKU Patients: Beyond Fat Mass.
Tummolo A, Carella R, Paterno G, Bartolomeo N, Giotta M, Dicintio A
Children (Basel). 2022; 9(9).
PMID: 36138662
PMC: 9497631.
DOI: 10.3390/children9091353.
The Challenges and Dilemmas of Interpreting Protein Labelling of Prepackaged Foods Encountered by the PKU Community.
Hall I, Pinto A, Evans S, Daly A, Ashmore C, Ford S
Nutrients. 2022; 14(7).
PMID: 35405967
PMC: 9003307.
DOI: 10.3390/nu14071355.
Management precautions for risk of obesity are necessary among infants with PKU carrying the rs113883650 variant of the LAT1 gene: A cross-sectional study.
Bik-Multanowski M, Didycz B, Bik-Multanowska K
PLoS One. 2022; 17(2):e0264084.
PMID: 35176108
PMC: 8853486.
DOI: 10.1371/journal.pone.0264084.
Engineering Organoids for Modeling of Phenylketonuria.
Borges A, Broersen K, Leandro P, Fernandes T
Front Mol Neurosci. 2022; 14:787242.
PMID: 35082602
PMC: 8784555.
DOI: 10.3389/fnmol.2021.787242.
Provision and Supervision of Food and Protein Substitute in School for Children with PKU: Parent Experiences.
Jones H, Pinto A, Evans S, Ford S, ODriscoll M, Buckley S
Nutrients. 2021; 13(11).
PMID: 34836117
PMC: 8621748.
DOI: 10.3390/nu13113863.
Telehealth and COVID-19: Empowering Standards of Management for Patients Affected by Phenylketonuria and Hyperphenylalaninemia.
Rovelli V, Zuvadelli J, Paci S, Ercoli V, Dionigi A, Selmi R
Healthcare (Basel). 2021; 9(11).
PMID: 34828453
PMC: 8622759.
DOI: 10.3390/healthcare9111407.
Nitrogen Balance after the Administration of a Prolonged-Release Protein Substitute for Phenylketonuria as a Single Dose in Healthy Volunteers.
Scheinin M, Junnila J, Reiner G, MacDonald A, Muntau A
Nutrients. 2021; 13(9).
PMID: 34579066
PMC: 8466970.
DOI: 10.3390/nu13093189.
Metabolic Control of Patients with Phenylketonuria in a Portuguese Metabolic Centre Comparing Three Different Recommendations.
Kanufre V, Almeida M, Sousa Barbosa C, Carmona C, Bandeira A, Martins E
Nutrients. 2021; 13(9).
PMID: 34578995
PMC: 8469656.
DOI: 10.3390/nu13093118.
A Three-Year Longitudinal Study Comparing Bone Mass, Density, and Geometry Measured by DXA, pQCT, and Bone Turnover Markers in Children with PKU Taking L-Amino Acid or Glycomacropeptide Protein Substitutes.
Daly A, Hogler W, Crabtree N, Shaw N, Evans S, Pinto A
Nutrients. 2021; 13(6).
PMID: 34204378
PMC: 8233747.
DOI: 10.3390/nu13062075.
Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria.
Qi Y, Patel G, Henshaw J, Gupta S, Olbertz J, Larimore K
Clin Transl Sci. 2021; 14(5):1894-1905.
PMID: 34057292
PMC: 8504851.
DOI: 10.1111/cts.13043.
Health economic burden of patients with phenylketonuria (PKU) - A retrospective study of German health insurance claims data.
Trefz F, Muntau A, Schneider K, Altevers J, Jacob C, Braun S
Mol Genet Metab Rep. 2021; 27:100764.
PMID: 34036045
PMC: 8138676.
DOI: 10.1016/j.ymgmr.2021.100764.